Journal article icon

Journal article

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

Abstract:

Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118. Plasma samples were collected before and after dose receipt on the first and last days of therapy, and fecal samples were collected on the last day of therapy. Samples were analyzed for fidaxomicin and OP-1118 (metabolite), using validated liquid chromatography/tand...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/cid/cis337

Authors


Miller, MA More by this author
Journal:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume:
55 Suppl 2
Issue:
SUPPL.2
Pages:
S116-S120
Publication date:
2012-08-05
DOI:
EISSN:
1537-6591
ISSN:
1058-4838
URN:
uuid:8de5c1d6-5adf-4692-a968-0b2ceeb1bdf8
Source identifiers:
344572
Local pid:
pubs:344572

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP